Seletracetam lithium  (Synonyms: Ucb 44212 lithium)

Seletracetam (Ucb 44212) lithium, as an analog of the antiepileptic agent Levetiracetam, is a SV2A modulator for the research of epilepsy^[1][2][3].

SV2A^[1]

Seletracetam lithium decreases seizure activity in a number of epilepsy models and binds to the synaptic vesicle protein SV2A^[2].
Seletracetam lithium decreases synaptic responses in a time-, frequency- and concentration-dependent manner^[2].
Seletracetam lithium modifies rates of presynaptic release^[2].
Seletracetam lithium inhibits high-voltage-activated Ca²⁺ currents and intracellular Ca²⁺ increase in rat cortical neurons in vitro^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

239.17

C₁₀H₁₄F₂LiN₂O₂

O=C([C@@H](N1C(C[C@H](C1)/C=C(F)\F)=O)CC)N.[Li]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Pollard JR, et al. Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy. Curr Opin Investig Drugs. 2008 Jan;9(1):101-7.  [Content Brief]

  [2]. Martella G, et al. Seletracetam (ucb 44212) inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro. Epilepsia. 2009 Apr;50(4):702-10.  [Content Brief]

  [3]. Yang X, et al. Seletracetam enhances short term depression in vitro. Epilepsy Res. 2015 Nov;117:17-22.  [Content Brief]